Systemic glucocorticoids

PreclinicalSmall molecule

Systemic glucocorticoids is one of 37 small molecule programs targeting Chronic Rhinosinusitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic RhinosinusitisActive, not recruiting

Chronic RhinosinusitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Chronic Rhinosinusitis

#DrugCompanyPhaseTrials

Flovent

GSK

Phase 3

2 2

Cinqair

Teva

Phase 3

2 3

Tezspire

AstraZeneca

Phase 3

1 4

Nurtec

Pfizer

Phase 3

1 5

Levaquin

WWim Janssens

Phase 3

2 6

PULMOZYME

Roche

Phase 3

1 7

Oxycontin

PProtega

Phase 3

1 8

Advil

KKenvue Brands

Phase 3

1 9

Fasenra

AstraZeneca

Phase 2

2 10

CM310

KKeymed Biosciences Co.Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Rhinosinusitis1 trial

Steroid-eluting Sinus Stent for Chronic Rhinosinusitis Patients With Uncontrolled Postoperative Symptoms

Recruiting·ZZheng Liu·N/A·NCT06198894·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Systemic glucocorticoids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Systemic glucocorticoids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Systemic glucocorticoids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zheng Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZheng Liu

Systemic glucocorticoids

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Rhinosinusitis1 trial

References

Drug Info

Quick Facts

Related News